Healthcare company Viatris Inc (NASDAQ:VTRS) on Wednesday announced positive top-line results from a Phase 3 study of EFFEXOR (venlafaxine) in Japanese adults with generalised anxiety disorder (GAD).
The study demonstrated the efficacy and safety of EFFEXOR in treating GAD, meeting both primary and secondary endpoints and confirming superiority compared to placebo.
Viatris plans to submit the results to the Pharmaceuticals and Medical Devices Agency (PMDA) in 2025.
EFFEXOR is currently approved in Japan for the indication of major depressive disorder in adults. For the indication of GAD, EFFEXOR has been approved in more than 80 countries outside of Japan.
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition